Abstract:Objective:To evaluate the clinical effects of mycophenolate mofetil (MMF) and cyclophosphamide(CTX) treatment for patients with antineutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV). Methodology:Thirty-five patients who had active AAV[15 male, 20 female: age(49.1±12.2)y], of whom 28 patients were MPO-ANCApositive and two were PR3-ANCA positive, were enrolled in this study. All patients had renal involvement with serum creatinine less than 500 μmol/L prior to the study and were received either MMF treatment (MMF group, n=18), or intermittent CTX pulse therapy (CTX group, n=17). The patients in both groups also received methylprednisolone (MP) pulse therapy followed by oral predenisone. The disease activity was monitored using the Birmingham Vasculitis Activity Score (BVAS). The chronic damage was measured by vasculitis damage index (VDI). The remission rate, drug-related adverse reactions and relapse were compared in the two groups. Results:The patients in the MMF group were treated with MMF for 6-24months and had a follow-up time ranged from 12 to 60 months (average 29.7±16.8) except 2 patients lost follow up after 6 months' treatment. The patients in the CTX group were followed up 12 to 63 months(average 28.5±14.6)except four patients dropped out. 17 of the 18 patients (94.4%) in the MMF group and 10 of the 13 patients (76.9%) in the CTX group had remission. At 3 months, 50% patients in MMF group, and 15.4% patients in CTX group had remission (P<0.05), while the remission rate were 77.8% and 61.5%, 100% and 81.8% at 6 months and 12 months respectively ( P>0.05). Two patients developed end stage renal failure in both groups during follow-up. At the last visit, 44.4% of MMF group and 15.4% of CTX group had their renal function recovered. The VDI scores after 12 months follow-up were significantly lower in the MMF group than that in the CTX group(P<0.05). Furthermore, 5 of the 12 ANCA positive patients (41.7%) in the MMF group and 1 of the 5 patients (20%) in the CTX group were ANCA negative after 12 months treatment. The decrement of ANCA titer was found in 50% of patients in the MMF group and 40% in the CTX group. Two patients in the MMF group (11.8%) and 3 patients (30%)in the CTX group relapsed. One patient died in each group. The side effects included pneumonia (one), herpes zoster (one) and gastro-intestinal symptoms (2 patients) in the MMF group, and leukocytopenia (one), severe gastro-intestinal symptoms(4 patients) in the CTX group. Conclusion:MMF was more effective than intermittent CTX pulse therapy in inducing remission, improving renal function and reducing serum ANCA level in patients with ANCA associated vasculitis.

Mycophenolate Mofetil Versus Intermittent Cyclophosphamide Pulse Therapy in Patients with Crescentic IgA Nephropathy

Mycophenolate Mofetil Versus Intravenous Pulse Cyclophosphamide in Induction Therapy of Crescentic Lupus Nephri-Tis

Effects of mycophenolate mofetil for patients with crescentic lupus nephritis.

Clinical study of mycophenolate mofetil therapy versus intermittent cyclophosphamide pulse treatment in lupus nephritis

Comparison of mycophenolate mofetil and cyclophosphamide treatment in patients with ANCA associated vasculitis

Effects Of Mycophenolate Mofetil Combined With Corticosteroids For Induction Therapy Of Microscopic Polyangiitis

Mycophenolate mofetil versus cyclophosphamide for inducing remission of ANCA vasculitis with moderate renal involvement.

Mycophenolate Mofetil Versus Intravenous Pulse Cyclophosphamide for Class Ⅳ Plus Ⅴ Lupus Nephritis

Mycophenolate Mofetil Therapy Versus Intermittent Cyclophosphamide Pulse Treatment in Patients with Severe Henoch-Schonlein Purpura Nephritis

Mycophenolate Mofetil Combined With Prednisone Versus Full-Dose Prednisone in IgA Nephropathy With Active Proliferative Lesions: A Randomized Controlled Trial

Mycophenolate Mofetil Vs Cyclophosphamide Therapy for Patients with Diffuse Proliferative Lupus Nephritis

Treatment of Membranous Nephropathy in Chinese Patients: Comparison of Rituximab and Intravenous Cyclophosphamide with Steroids

The Efficacy and Safety of Tacrolimus Monotherapy in Adult-Onset Nephrotic Syndrome Caused by Idiopathic Membranous Nephropathy

Early Initiation of Tacrolimus or Cyclophosphamide Therapy for Idiopathic Membranous Nephropathy with Severe Proteinuria.

Mycophenolate Mofetil or Tacrolimus Compared with Intravenous Cyclophosphamide in the Induction Treatment for Active Lupus Nephritis

Combination Therapy of Prednisone and Cyclophosphamide for Patients with Idiopathic Membranous Nephropathy:A Prospective Randomized Controlled Trial

Comparison of the efficacy and safety of tacrolimus monotherapy and cyclophosphamide combined with glucocorticoid in the treatment of adult primary membranous nephropathy: protocol of a multicenter, randomized, controlled, open study

Cyclosporine A and Tacrolimus Combined with Enteric-Coated Mycophenolate Sodium Influence the Plasma Mycophenolic Acid Concentration - a Randomised Controlled Trial in Chinese Live Related Donor Kidney Transplant Recipients

Cyclophosphamide Versus Leflunomide Combined with Prednisone Respectively in Treatment of Chronic Progressive IgA Nephropathy

Effect of Shen Xian Kang Decoction Combined Mycophenolate Mofetil in Patients with Proliferative Sclerosing IgA Nephropathy

The combination of mycophenolate mofetil with corticosteroids induces remission of Henoch-Schönlein purpura nephritis.